TREVI THERAPEUTICS

trevi-therapeutics-logo

Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinsonโ€™s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.

#SimilarOrganizations #People #Financial #Website #More

TREVI THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
2011-01-01

Address:
Sandy Hook, Connecticut, United States

Country:
United States

Website Url:
http://www.trevitherapeutics.com

Total Employee:
11+

Status:
Active

Contact:
203-304-2499

Email Addresses:
[email protected]

Total Funding:
156.53 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Content Delivery Network Google Universal Analytics


Similar Organizations

aimmune-therapeutics-logo

Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.

context-therapeutics-logo

Context Therapeutics

Context Therapeutics is a clinical-stage biopharmaceutical company.

edgewise-therapeutics-logo

Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

novabay-pharmaceuticals-logo

NovaBay Pharmaceuticals

NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.

reata-pharmaceuticals-logo

Reata Pharmaceuticals

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.


Current Advisors List

jennifer-l-good_image

Jennifer L. Good Board Member @ Trevi Therapeutics
Board_member
2011-03-01

annie-mitsak_image

Annie Mitsak Board Member @ Trevi Therapeutics
Board_member
2018-08-01

anne-m-vanlent_image

Anne M. VanLent Board Member @ Trevi Therapeutics
Board_member
2018-10-01

mette-kirstine-agger_image

Mette Kirstine Agger Board Member @ Trevi Therapeutics
Board_member
2017-07-01

david-meeker_image

David Meeker Board Chairman @ Trevi Therapeutics
Board_member
2017-07-01

ed-mathers_image

Ed Mathers Board Member @ Trevi Therapeutics
Board_member
2017-07-01

eran-nadav_image

Eran Nadav Board Member @ Trevi Therapeutics
Board_member

michael-t-heffernan_image

Michael T. Heffernan Board Member @ Trevi Therapeutics
Board_member

Current Employees Featured

thomas-r-sciascia_image

Thomas R. Sciascia
Thomas R. Sciascia Chief Medical Officer @ Trevi Therapeutics
Chief Medical Officer

jennifer-l-good_image

Jennifer L. Good
Jennifer L. Good Co-Founder, President and CEO @ Trevi Therapeutics
Co-Founder, President and CEO
2011-03-01

christopher-seiter_image

Christopher Seiter
Christopher Seiter CFO @ Trevi Therapeutics
CFO

william-p-forbes_image

William P. Forbes
William P. Forbes Chief Development Officer (CDO) @ Trevi Therapeutics
Chief Development Officer (CDO)
2021-02-01

helena-brett-smith_image

Helena Brett-Smith
Helena Brett-Smith Chief Development Officer @ Trevi Therapeutics
Chief Development Officer

Founder


jennifer-l-good_image

Jennifer L. Good

thomas-r-sciascia_image

Thomas R. Sciascia

Stock Details


Company's stock symbol is NASDAQ:TRVI

Investors List

fairmount-funds-management_image

Fairmount Funds Management

Fairmount Funds Management investment in Post-IPO Equity - Trevi Therapeutics

venrock-healthcare-partners_image

Venrock Healthcare Capital Partners

Venrock Healthcare Capital Partners investment in Post-IPO Equity - Trevi Therapeutics

frazier-life-sciences_image

Frazier Life Sciences

Frazier Life Sciences investment in Post-IPO Equity - Trevi Therapeutics

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Post-IPO Equity - Trevi Therapeutics

omega-funds_image

Omega Funds

Omega Funds investment in Series C - Trevi Therapeutics

tpg-biotech_image

TPG Biotech

TPG Biotech investment in Series C - Trevi Therapeutics

lundbeckfond-ventures_image

Lundbeckfonden Ventures

Lundbeckfonden Ventures investment in Series C - Trevi Therapeutics

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Series C - Trevi Therapeutics

tpg-biotech_image

TPG Biotech

TPG Biotech investment in Series C - Trevi Therapeutics

lundbeckfond-ventures_image

Lundbeckfonden Ventures

Lundbeckfonden Ventures investment in Series C - Trevi Therapeutics

Official Site Inspections

http://www.trevitherapeutics.com Semrush global rank: 7.6 M Semrush visits lastest month: 455

  • Host name: 32.51.180.107.host.secureserver.net
  • IP address: 107.180.51.32
  • Location: Scottsdale United States
  • Latitude: 33.6013
  • Longitude: -111.8867
  • Metro Code: 753
  • Timezone: America/Phoenix
  • Postal: 85260

Loading ...

More informations about "Trevi Therapeutics" on Search Engine